Three approved drugs, i.e., selegiline and rasagiline, enter in propargylamine class and are somewhat selective for MAO-B, while safinamide, a selective, reversible inhibitor, is used for the treatment of Parkinson’s disease [10]. This evidence concerns the gene MAOB and Parkinson disease.